196 related articles for article (PubMed ID: 24604329)
1. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
[TBL] [Abstract][Full Text] [Related]
2. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo.
Tang M; Zu C; He A; Wang W; Chen B; Zheng X
Drug Des Devel Ther; 2015; 9():3301-12. PubMed ID: 26203222
[TBL] [Abstract][Full Text] [Related]
4. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
[TBL] [Abstract][Full Text] [Related]
5. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.
Yang Y; Xu H; Huang W; Ding M; Xiao J; Yang D; Li H; Liu XY; Chu L
J Cell Mol Med; 2015 May; 19(5):915-23. PubMed ID: 25683371
[TBL] [Abstract][Full Text] [Related]
6. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
[TBL] [Abstract][Full Text] [Related]
7. Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.
Zhang Y; Qin X; Zhang Y; Zhao L; Wang Y; Liu X; Yao L
J Cancer Res Clin Oncol; 2008 Feb; 134(2):219-26. PubMed ID: 17632733
[TBL] [Abstract][Full Text] [Related]
8. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
[TBL] [Abstract][Full Text] [Related]
9. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
[TBL] [Abstract][Full Text] [Related]
10. Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers.
Zhao Y; Li Y; Wang Q; Wang L; Yang H; Li M
Mol Cell Biochem; 2011 Jul; 353(1-2):93-9. PubMed ID: 21437625
[TBL] [Abstract][Full Text] [Related]
11. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.
Yang Y; Xu H; Shen J; Yang Y; Wu S; Xiao J; Xu Y; Liu XY; Chu L
Cell Death Dis; 2015 May; 6(5):e1760. PubMed ID: 25973680
[TBL] [Abstract][Full Text] [Related]
12. E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma.
Wang H; Satoh M; Chen GP; Li DC; Hamada H; Arai Y
Chin Med J (Engl); 2011 Apr; 124(7):1082-7. PubMed ID: 21542972
[TBL] [Abstract][Full Text] [Related]
13. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.
Cai Y; Liu X; Huang W; Zhang K; Liu XY
Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):535-43. PubMed ID: 22635106
[TBL] [Abstract][Full Text] [Related]
16. microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer.
Zhao Y; Li Y; Wang L; Yang H; Wang Q; Qi H; Li S; Zhou P; Liang P; Wang Q; Li X
J Exp Clin Cancer Res; 2013 Feb; 32(1):10. PubMed ID: 23442927
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus.
Gao H; Zhang X; Ding Y; Qiu R; Hong Y; Chen W
Technol Cancer Res Treat; 2019; 18():1533033819853290. PubMed ID: 31138083
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
Kasman L; Lu P; Voelkel-Johnson C
Cancer Gene Ther; 2007 Mar; 14(3):327-34. PubMed ID: 17186014
[TBL] [Abstract][Full Text] [Related]
19. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
20. Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma.
Qiu S; Ruan H; Pei Z; Hu B; Lan P; Wang J; Zhang Z; Gu J; Sun L; Qian C; Liu X; Qi Y
J Interferon Cytokine Res; 2004 Apr; 24(4):219-30. PubMed ID: 15144568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
